Bringing New Hope to the Hardest-to-Reach Tumors
ANGELIS Oncology is advancing ANG038, a targeted, long-acting therapy designed for patients with difficult CNS cancers.
Where CNS Oncology Meets Targeted Drug Delivery
Our work is grounded in published research on long-acting SN-38 delivery, brain tumor penetration, and therapeutic strategies for cancers with DNA damage response vulnerabilities.